Year 2018 / Volume 110 / Number 2
Letter to the Editor
Post-transplant lymphoproliferative disease after liver transplantation

131-132

DOI: 10.17235/reed.2017.5387/2017

José Ignacio Herrero, Carlos Panizo,

Abstract
We have read the article “Post-transplant lymphoproliferative disease in liver transplant recipients” with great interest. This article reports a series of liver transplant recipients with post-transplant lymphoproliferative disease (PTLD). The effect on patient survival and the potential benefit of rituximab-based therapy are highlighted. Rituximab is a chimeric antibody against the CD20 surface marker. This marker is found in most PTLD of a B cell origin. A recent study from our center also highlighted the role of rituximab in PTLD therapy (3). The overall response rate of patients treated with rituximab was 66% in both series. In our series, this included heart, kidney and liver transplant recipients. Rituximab-based therapy was also associated with an increased overall survival. Rituximab should be considered as part of the first-line therapy in patients with PTLD when CD20 expression is present.
Share Button
New comment
Comments
No comments for this article
References
Rubio-Manzanares Dorado M, Alamo Martinez JM, Bernal Bellido C, et al. Síndrome linfoproliferativo en el trasplante hepatico. Rev Esp Enferm Dig 2017; 109: 406-413.
Maloney DG. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med 2012;366:2008-2016.
Martinez-Calle N, Alfonso A, Rifon J, et al. First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-center study. Eur J Hematol 2016;98:38-43.
Related articles

Editorial

Early liver transplantation in severe alcohol-associated hepatitis

DOI: 10.17235/reed.2024.10881/2024

Letter

Abernethy syndrome as a cause of liver transplantation

DOI: 10.17235/reed.2024.10561/2024

Digestive Diseases Image

Posterior reversible encephalopathy syndrome (PRES) in post liver transplantation

DOI: 10.17235/reed.2022.8694/2022

Letter

Ertapenem neurotoxicity in liver transplantation

DOI: 10.17235/reed.2021.8469/2021

Digestive Diseases Image

Duodenal-type follicular lymphoma: a silent tumor

DOI: 10.17235/reed.2021.8149/2021

Digestive Diseases Image

Percutaneous treatment of a splenorenal shunt with an atrial septal closure device

DOI: 10.17235/reed.2020.7701/2020

Review

Physical frailty in liver transplantation

DOI: 10.17235/reed.2020.7448/2020

Letter

Management of hepatic artery aneurysms

DOI: 10.17235/reed.2020.7219/2020

Digestive Diseases Image

Epithelioid hemangioendothelioma: a rare cause of a liver tumor

DOI: 10.17235/reed.2020.7127/2020

Letter

Follicular non-Hodgkin lymphoma with primary colonic involvement

DOI: 10.17235/reed.2020.6986/2020

Letter to the Editor

Liver metastasis from colorectal cancer 12 years after liver transplantation

DOI: 10.17235/reed.2017.4507/2016

Citation tools
Herrero J, Panizo C. Post-transplant lymphoproliferative disease after liver transplantation. 5387/2017


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1183 visits.
This article has been downloaded 286 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 20/11/2017

Accepted: 28/11/2017

Online First: 09/01/2018

Published: 31/01/2018

Article Online First time: 50 days

Article editing time: 72 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2024 y Creative Commons. The Spanish Journal of Gastroenterology